Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tretinoin may help cancer cells become more like normal cells, and to grow and
spread more slowly. Drugs used in chemotherapy, such as arsenic trioxide and idarubicin, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing. Giving tretinoin together with arsenic trioxide with or without
idarubicin may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving tretinoin together with arsenic
trioxide with or without idarubicin works in treating patients with acute promyelocytic
leukemia.